Personalized mRNA & Therapeutic Protein Research
How our in-silico research approach works
Research-only. Computational concepts require laboratory, preclinical, clinical, and regulatory validation before any medical use.
A. Personalized Cancer mRNA Vaccine Concepts
We investigate whether a personalized mRNA vaccine concept is scientifically supportable for a given case — step by step, with explicit uncertainties at every stage.
Understand the Individual Research Case
We begin with appropriately authorized, de-identified research information where available. Cases vary biologically, and personalization requires relevant case-specific evidence — not a generic template.
- ▸Cancer type and biological characteristics
- ▸Tumor and matched normal sequencing results
- ▸Available tumor RNA-expression information
- ▸Research HLA genotype
- ▸Published evidence for relevant mutations
- ▸Known scientific uncertainties
Compare Cancer and Normal Cells
Cancer develops through alterations in cellular regulation, including genetic mutations and abnormal gene expression. Using Python and bioinformatics, researchers can compare tumor and normal datasets to investigate candidate somatic mutations.
The objective is to identify changes associated with the tumor that may produce altered proteins.
Investigate Neoantigens
Certain tumor-specific protein alterations may create potential neoantigens. Computational analysis evaluates the evidence behind each candidate. Not every mutation produces a useful neoantigen.
- ▸Whether the alteration is supported by the data
- ▸Whether the relevant protein is expressed
- ▸Whether the alteration may produce a distinguishable peptide
- ▸Whether the proposed target is biologically relevant
Personalized HLA Analysis
HLA molecules present peptide fragments to immune cells. Different HLA profiles may present different peptides, so computational HLA-binding and antigen-presentation predictions can help prioritize candidates for research.
MHC Class I and MHC Class II play different roles in T-cell immune recognition. Predicted HLA binding does not prove a clinically meaningful immune response.
Apply the Rami R10CF Framework
Our proposed Ten-Checkpoint Computational Research Framework organizes the evidence and uncertainties for each candidate:
- 1.Antigen relevance
- 2.Target confirmation
- 3.Human similarity & safety screening
- 4.Sequence optimization assessment
- 5.RNA structure assessment
- 6.MHC Class I prediction
- 7.MHC Class II prediction
- 8.HLA coverage assessment
- 9.Structural feasibility
- 10.Manufacturability assessment
A weighted computational score can organize research evidence and uncertainties. The score is an internal research-prioritization tool, not a clinically validated prediction of vaccine success.
Protein Structure Analysis
AI protein-structure prediction and molecular modeling may help investigate structural characteristics and mutation-related changes. AlphaFold and related tools are used conceptually.
Predicted structures have limitations and do not independently demonstrate biological function or antigen effectiveness.
Preliminary mRNA Research Blueprint
The computational findings may inform a hypothetical mRNA vaccine research blueprint. We describe the scientific considerations at a conceptual level and do not generate or present a candidate sequence as a proven vaccine.
- ▸Candidate antigen rationale
- ▸RNA sequence-design considerations
- ▸RNA structural characteristics
- ▸Translational feasibility
- ▸Immune-response uncertainties
- ▸Preliminary manufacturability considerations
Independent Validation
Computational research and experimental development are distinct. Appropriate laboratory assessment, functional testing, preclinical investigation, clinical trials, and regulatory evaluation are required before any medical use.
B. Therapeutic Protein Engineering
Our research also investigates medical challenges beyond cancer vaccines — using problem-specific strategies rather than a single framework.
Identify the Biological Problem
First we investigate what is happening at the molecular level. Each problem may require a different therapeutic strategy.
- ▸A missing or defective enzyme
- ▸A harmful protein interaction
- ▸An abnormal immune response
- ▸An autoantibody targeting healthy tissue
- ▸A toxic small molecule requiring selective binding
Select the Appropriate Research Strategy
Three separate research approaches, each matched to a different class of biological problem:
Investigate the role of the IDS enzyme and the consequences of deficient enzyme activity. Explore hypothetical protein-replacement or mRNA-encoded enzyme approaches, with attention to protein function, cellular delivery, stability, and safety limitations.
Investigate whether a hypothetical engineered binder or decoy might interfere with a disease-associated molecular interaction. Specificity matters — the goal is to avoid interfering with normal physiological functions.
Investigate the concept of proteins that could selectively recognize or bind harmful molecules — considering computational binding, molecular selectivity, stability, and biological compatibility. This is unvalidated research; it is not an established fentanyl antidote or an alternative to naloxone and emergency treatment.
AI-Assisted Protein Engineering
Python and computational biology tools can organize evidence, compare predictions, and document uncertainty across these dimensions.
- ▸Protein sequence and structure relationships
- ▸Protein folding
- ▸Molecular interaction predictions
- ▸Candidate binding characteristics
- ▸Structural stability
- ▸Specificity and potential off-target interactions
- ▸Immunogenicity concerns
- ▸Protein delivery challenges
Case-by-Case Computational Assessment
The research approach must depend on the biological problem. A missing enzyme, a harmful autoantibody, and a toxic small molecule require different targets, modeling methods, and validation approaches.
We use a research-specific evaluation framework for protein engineering and do not apply the vaccine-focused R10CF score indiscriminately to every protein therapy.
Prepare a Scientific Research Blueprint
All engineered therapeutic concepts require independent experimental verification before any medical use.
- ▸Biological problem analysis
- ▸Target and mechanism-of-action research
- ▸Computational protein evaluation
- ▸Predicted structure and interaction reports
- ▸Specificity and safety considerations
- ▸Feasibility assessment
- ▸Research limitations
- ▸Recommended validation questions
Example Applications We Investigate
Research-only. In-silico concepts require laboratory, preclinical, clinical, and regulatory validation before any medical use. We do not claim validated prediction accuracy, FDA approval, or proven therapeutic benefit.